Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis marker
BACKGROUND: Evidence of increased bone marrow vascularity in multiple myeloma (MM) has led to the ...
Multiple myeloma (MM) is a clonal disorder of plasma cells that is considered incurable using the cu...
Thalidomide, an oral agent with antiangiogenic and immunomodulatory properties, is being investi-gat...
haematologica/the hematology journal | 2007; 92(08) | 1075 | Patients with multiple myeloma treated...
PurposeTo study the antiangiogenic effect of thalidomide.Patients and MethodsThe expression of key a...
Thalidomide acts on the microenvironment of myelodysplastic syndromes (MDS) by influencing cytokine ...
PURPOSE: To study the antiangiogenic effect of thalidomide. PATIENTS AND METHODS: The expression...
Background and Objectives: In vitro studies suggest that thalidomide has an immunoregulatory role an...
Thalidomide, an oral agent with antiangiogenic and immunomodulatory properties, is being investigate...
We treated with thalidomide seven patients with primary MDS and observed reduction of the transfusio...
Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmun...
To determine the mechanism of thalido-mide’s antimyeloma efficacy, we studied the drug’s activity in...
BACKGROUND: Evidence of increased bone marrow vascularity in multiple myeloma (MM) has led to the u...
Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma Thalidomide has shown effica...
INTRODUCTION: Recently, a report has suggested the efficacy and safety of thalidomide in refractory ...
BACKGROUND: Evidence of increased bone marrow vascularity in multiple myeloma (MM) has led to the ...
Multiple myeloma (MM) is a clonal disorder of plasma cells that is considered incurable using the cu...
Thalidomide, an oral agent with antiangiogenic and immunomodulatory properties, is being investi-gat...
haematologica/the hematology journal | 2007; 92(08) | 1075 | Patients with multiple myeloma treated...
PurposeTo study the antiangiogenic effect of thalidomide.Patients and MethodsThe expression of key a...
Thalidomide acts on the microenvironment of myelodysplastic syndromes (MDS) by influencing cytokine ...
PURPOSE: To study the antiangiogenic effect of thalidomide. PATIENTS AND METHODS: The expression...
Background and Objectives: In vitro studies suggest that thalidomide has an immunoregulatory role an...
Thalidomide, an oral agent with antiangiogenic and immunomodulatory properties, is being investigate...
We treated with thalidomide seven patients with primary MDS and observed reduction of the transfusio...
Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmun...
To determine the mechanism of thalido-mide’s antimyeloma efficacy, we studied the drug’s activity in...
BACKGROUND: Evidence of increased bone marrow vascularity in multiple myeloma (MM) has led to the u...
Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma Thalidomide has shown effica...
INTRODUCTION: Recently, a report has suggested the efficacy and safety of thalidomide in refractory ...
BACKGROUND: Evidence of increased bone marrow vascularity in multiple myeloma (MM) has led to the ...
Multiple myeloma (MM) is a clonal disorder of plasma cells that is considered incurable using the cu...
Thalidomide, an oral agent with antiangiogenic and immunomodulatory properties, is being investi-gat...